Table 1.
Properties of evaluated commercially available Aβ assays. The various capture and detection antibodies employed in the different Aβ 42 immunoassays. The differences in antibody epitope recognition and the part of CSF diluted in buffer during the incubation render methodological differences both qualitatively and quantitatively. aa, amino acids.
| Innotest Elisa | Innotest Elisa (4G8) | The genetics | INNO-BIAAlzBio3 | INNO-BIAAβ forms | MSD Triplex | |
|---|---|---|---|---|---|---|
| Capture (epitope) | 21F12 (42 C-terminal) |
21F12 (42 C-terminal) |
W02 (aa 5–8) |
4D7A3 (42 C-terminal) |
21F12 (42 C-terminal) |
Not declared (42 C-terminal) |
| Detection (epitope) | 3D6 (aa 1–5) |
4G8 (aa 17–24) |
G2-13 (42 C-terminal) |
3D6 (aa 1–5) |
3D6 (aa 1–5) |
4G8 (aa 17–24) |
| CSF (% v/v) |
25 | 25 | 50 | 75 | 75 | 50 |
| Aβ | 1–42 | x-42 | x-42 | 1–42 | 1–42 | x-42 |